Tarsus Pharmaceuticals, Inc. $TARS Stock Holdings Increased by TD Asset Management Inc

TD Asset Management Inc boosted its holdings in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 21.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 52,692 shares of the company’s stock after purchasing an additional 9,400 shares during the period. TD Asset Management Inc owned approximately 0.12% of Tarsus Pharmaceuticals worth $3,131,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in TARS. Osaic Holdings Inc. increased its holdings in shares of Tarsus Pharmaceuticals by 779.1% in the second quarter. Osaic Holdings Inc. now owns 2,778 shares of the company’s stock valued at $113,000 after buying an additional 2,462 shares in the last quarter. West Wealth Group LLC acquired a new position in shares of Tarsus Pharmaceuticals in the 3rd quarter worth $202,000. Valeo Financial Advisors LLC acquired a new stake in shares of Tarsus Pharmaceuticals during the third quarter worth $209,000. Tower Research Capital LLC TRC lifted its holdings in shares of Tarsus Pharmaceuticals by 220.3% during the second quarter. Tower Research Capital LLC TRC now owns 4,045 shares of the company’s stock valued at $164,000 after purchasing an additional 2,782 shares during the last quarter. Finally, Oppenheimer & Co. Inc. acquired a new position in shares of Tarsus Pharmaceuticals in the 3rd quarter valued at $247,000. Institutional investors and hedge funds own 90.01% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. Oppenheimer boosted their price objective on Tarsus Pharmaceuticals from $95.00 to $105.00 and gave the stock an “outperform” rating in a report on Wednesday, February 25th. Guggenheim lifted their price objective on shares of Tarsus Pharmaceuticals from $87.00 to $90.00 and gave the stock a “buy” rating in a research report on Wednesday, February 25th. The Goldman Sachs Group reissued a “neutral” rating and set a $68.00 target price on shares of Tarsus Pharmaceuticals in a research note on Thursday, February 5th. Mizuho began coverage on Tarsus Pharmaceuticals in a report on Thursday, November 20th. They issued an “outperform” rating and a $100.00 target price for the company. Finally, Zacks Research downgraded Tarsus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 25th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Tarsus Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $87.00.

Insider Buying and Selling

In related news, CEO Bobak R. Azamian sold 6,000 shares of the company’s stock in a transaction on Wednesday, December 24th. The shares were sold at an average price of $82.51, for a total value of $495,060.00. Following the completion of the sale, the chief executive officer directly owned 857,991 shares in the company, valued at approximately $70,792,837.41. This represents a 0.69% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Dianne C. Whitfield sold 7,397 shares of the stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $80.10, for a total transaction of $592,499.70. Following the transaction, the insider directly owned 38,958 shares in the company, valued at $3,120,535.80. The trade was a 15.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 8.97% of the stock is owned by insiders.

Tarsus Pharmaceuticals Price Performance

TARS opened at $76.20 on Thursday. The stock has a fifty day moving average price of $71.65 and a 200 day moving average price of $69.21. The company has a current ratio of 3.85, a quick ratio of 3.82 and a debt-to-equity ratio of 0.21. Tarsus Pharmaceuticals, Inc. has a 1 year low of $38.51 and a 1 year high of $85.25. The stock has a market cap of $3.24 billion, a price-to-earnings ratio of -47.04 and a beta of 0.55.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its quarterly earnings results on Monday, February 23rd. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.01). The firm had revenue of $151.67 million for the quarter, compared to analyst estimates of $144.56 million. Tarsus Pharmaceuticals had a negative net margin of 14.72% and a negative return on equity of 19.63%. Analysts forecast that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current fiscal year.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.